Accessibility and ADA statement
PeptideHelper.org is committed to making its content usable by the widest possible audience, including people who rely on assistive technology. We treat accessibility as an ongoing obligation, not a one-time checklist. This statement describes our target, the measures we take, where we currently fall short, and how to reach us about a barrier.
Legal framework
This statement is published with reference to the Americans with Disabilities Act, Section 508 of the Rehabilitation Act, the European Accessibility Act and the harmonised standard EN 301 549, and comparable accessibility legislation. Those frameworks converge on the Web Content Accessibility Guidelines as the technical benchmark.
Conformance target
We aim to conform to the Web Content Accessibility Guidelines (WCAG) 2.2 at Level AA. This is a statement of target and of ongoing effort, not a certified claim of full conformance. Conformance has been assessed by self evaluation rather than by third-party audit, and known gaps are listed under Known limitations below. We would rather state this accurately than claim a conformance level we have not independently verified.
Measures we take
- Semantic structure: pages use HTML landmarks (header, nav, main, footer) and a logical heading order so screen-reader users can navigate by region and heading.
- Keyboard operability: every interactive control (links, buttons, filters, the dosage calculator, the interaction evaluator, the protocol builder) is reachable and operable with the keyboard alone. A "Skip to main content" link is the first focusable element on every page.
- Visible focus: keyboard focus is always shown with a visible outline.
- Labels and names: form fields and icon-only controls carry accessible names so their purpose is announced by assistive technology.
- Color and contrast: text and essential interface elements meet the WCAG AA contrast ratio in both light and dark themes, and color is never the only way information is conveyed.
- Zoom and reflow: content reflows without loss of function up to 200% zoom and adapts to small mobile viewports.
- Reduced motion: animations and transitions are suppressed for visitors whose system requests reduced motion.
- Target size and dragging: interactive controls are sized for touch, and no essential action depends on a dragging movement alone.
Compatibility
The Site is built to work with current versions of major browsers (Chrome, Edge, Firefox, Safari) on desktop and mobile, used together with current screen readers such as NVDA, JAWS, and VoiceOver. It does not depend on any browser plug-in.
Known limitations
Despite our efforts, some areas may not yet be fully accessible:
- Dense data tools: the interaction matrix and comparison tables present a large grid of information; we are continuing to improve their screen-reader narration.
- Generated exports: PDF and image exports of dosing schedules are visual artifacts and may not carry full structural tagging.
- Third-party content: outbound vendor links lead to sites whose accessibility we do not control.
Where a feature is not yet fully accessible, the underlying information is also available in text form elsewhere on the Site.
Feedback and complaints
If you encounter a barrier, or need information from this Site in a different format, email contact@peptidehelper.org. Tell us the page, what you were trying to do, and the assistive technology you were using. We aim to acknowledge accessibility feedback within five business days and to fix confirmed barriers as a priority.
If a response does not resolve the problem, say so in reply and we will escalate it for a further review. Alternative formats of any reference page can be provided on request at no charge.
Assessment
This statement reflects ongoing self-evaluation: automated testing (axe-core) run against the Site's primary pages as part of the build, plus manual keyboard and screen-reader checks. It is reviewed as the Site evolves and at least annually.
Effective date: August 5, 2026.